XNPT - The PHN indication is based on a single PII trial. That appears to satisfy the 505b2 pathway to some respect. The only question I have is about the dosage. The recommended dosage for Horizant is 600 mg daily. The PHN approval is for 600mg BID. Will this be an issue especially with the cancer issue they had earlier.
Market Data 
Markets 
AI
